Nova Leap Health (NLH) Q2 2025 earnings summary

Executive summary

• Achieved record consolidated quarterly revenues, gross margin, and Adjusted EBITDA in Q2 2025.

• Set new highs in both Canadian and U.S. operating segments for revenue and gross margin.

• Growth driven by organic expansion and a strategic acquisition in Nova Scotia.

• Insider ownership increased to 42.26% as directors and officers raised their holdings.

Financial highlights

• Q2 2025 revenues reached $8,021,072, up 13.1% from Q1 2025 and 26.5% year-over-year.

• Adjusted EBITDA for Q2 2025 was $577,907, a 99.9% increase from Q1 2025 and 41.7% higher than Q2 2024.

• Gross profit margin was 40.2% in Q2 2025, compared to 39.0% in Q1 2025 and 38.4% in Q2 2024.

• Income from operating activities in Q2 2025 was $350,439, up from $75,152 in Q1 2025 and $247,709 in Q2 2024.

• Net loss for Q2 2025 was $484,008, compared to a net loss of $78,299 in Q1 2025 and net income of $226,998 in Q2 2024.

Outlook and guidance

• Management expects continued growth through organic expansion and further acquisitions.

• Focus remains on operational discipline, technology integration, and scaling productivity.

• Forward-looking statements highlight anticipated revenue and Adjusted EBITDA margin growth.